Efzilonkofusp alfa

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameEfzilonkofusp alfa
Drug Alias NameGI-102
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsApoptosis inhibitorsCell death stimulants +[5] 
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSkin MelanomaSolid tumoursSoft Tissue Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGI Innovation Inc
China Registration ClassN/A

Develop Information

Active Companiesi.DivineMerck Sharp & Dohme CorpMayo Clinic +[6] 
Inactive CompaniesN/A
Active IndicationsSkin MelanomaSolid tumoursSoft Tissue Neoplasms +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A